References
- Aronsohn, A., & Reau, N. (2009). Long-term outcomes after treatment with interferon and ribavirin in HCV patients. Journal of Clinical Gastroenterology, 43, 661–671. doi:10.1097/MCG.0b013e31819f66e2.
- Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3, 77–101. doi:10.1191/1478088706qp063oa.
- Commonwealth of Australia (2010). Third National Hepatitis C Strategy 2010–2013. Australian Government Department of Health and Ageing. Retrieved from http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-hcv/$File/hcv.pdf
- Dieperink, E., Ho, S.B., Thuras, P., & Willenbring, M.L. (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics, 44, 104–112. Retrieved from http://dx.doi.org/10.1176/appi.psy.44.2.104
- Fried, M.W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36(Suppl. 1), 237–244. doi:10.1053/jhep.2002.36810.
- Gayet, A.R., Plaisance, P., Bergmann, J.F., & Mouly, S. (2010). Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-2a and ribavirin: A case report and literature review. Clinical Medicine and Research, 8, 163–167. doi:10.3121/cmr.2010.886.
- Hepatitis NSW Inc (2011). Glen’s story: Dealing with deniers. Hep Review, 73, 46. Retrieved from http://hepmagazines.realviewtechnologies.com/?xml=Hep_C_Review&iid=48766
- Hepatitis NSW Inc (2010). Treatment side effects: Mental. Hepatitis C Factsheets, 1–4. Retrieved from http://www.hep.org.au/documents/factsheets/TreatmentSideEffectsMental2010.pdf
- Hopwood, M., & Treloar, C. (2007). Pre-treatment preparation and management of interferon-based therapy for hepatitis C virus infection. Journal of Advanced Nursing, 59, 248–254. doi:10.1111/j.1365-2648.2007.04305.x.
- Jensen, D.M. (2011). A new era of hepatitis C therapy begins [Editorial]. New England Journal of Medicine, 364, 1272–1274. doi:10.1056/NEJMe1100829.
- Lawrence, C. (2011, March). Chris’ story: Dealing with the after-effects. Hepatitis Review, 72, 46. Retrieved from http://hepmagazines.realviewtechnologies.com/?xml=Hep_C_Review&iid=46790
- McNally, S., Temple-Smith, M., & Pitts, M. (2005). Making decisions about hepatitis C treatment [Report No. 49]. Melbourne: The Australian Research Centre in Sex, Health and Society, La Trobe University. Retrieved from http://www.latrobe.edu.au/arcshs/downloads/arcshs-research-publications/making_decisions_about_hepc_treatment.pdf
- Meyers, C.A., Scheibel, R.S., & Forman, A.D. (1991). Persistent neurotoxicity of systematically administered interferon-alpha. Neurology, 41, 672–676.
- Raison, C.L., Demetrashvili, M., Capuron, L., & Miller, A.H. (2005). Neuropsychiatric adverse effects of interferon-alpha: Recognition and management. CNS Drugs, 19, 105–123. doi: 1172-7047/05/0002-0105/$34.95/0.
- Reichenberg, A., Gorman, J.M., & Dieterich, D.T. (2005). Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. AIDS, 19(Suppl. 3), 174–178.
- St. John, T.M., & Sandt, L. (2005). The hepatitis C crisis. Ethnicity and Disease, 15(Suppl. 2), 52–57.
- Tomer, Y. (2010). Hepatitis C and interferon induced thyroiditis. Journal of Autoimmunity, 34, 322–326. doi:10.1016/j.jaut.2009.11.008.
- Treloar, C., & Hopwood, M. (2008). “Look, I’m fit, I’m positive and I’ll be all right, thank you very much”: Coping with hepatitis C treatment and unrealistic optimism. Psychology, Health and Medicine, 13, 360–366. doi:10.1080/13548500701477532.
- Ware, J.E., Jr, Bayliss, M., Mannocchia, M.S., Davis, G.L., & the International Hepatitis Interventional Therapy Group (1999). Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology, 30, 550–555.